Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(2 sites)

Japan

Osaka International Cancer Institute, Osaka, Osaka

Kyusyu University Hospital, Fukuoka